← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeiGene

FDA approvalNew therapyEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Single-agent treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma after systemic chemotherapy that did not include a PD-1 or PD-L1 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The initial U.S. approval added another checkpoint inhibitor for the specified previously treated esophageal cancer population.

What research teams should watch

Confirm squamous histology and reconcile all prior checkpoint exposure before applying this historical indication.

PRIMARY RECORDS

Sources